Hansa Biopharma AB (OSTO:HNSA)
kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Q2 2021 Hansa Biopharma AB Earnings Call Transcript

Jul 15, 2021 / 12:00PM GMT
Release Date Price: kr114.2 (-17.19%)
Operator

Hello, and welcome to Hansa Biopharma Interim Report for January to June 2021. (Operator Instructions)

Today, I am pleased to present CEO, Søren Tulstrup. Please begin your meeting.

SÃ;ren Tulstrup;publ;President;CEO
Hansa Biopharma AB

¸ - ()-&

Thank you, moderator. Good afternoon to those of you in Europe, and good morning to those in the U.S. Welcome to the Hansa Biopharma conference call on the first half results of 2021.

I'm Søren Tulstrup, CEO of Hansa. With me today, I have our CFO, Donato Spota; as well as our Head of Investor Relations, Klaus Sindahl.

Today, we'll review the overall progress and highlights of our business in the first half of 2021 and provide a preview of our near-term milestones. Our presentation should take around 15 minutes. And after that, we'll take your questions.

Turn to Slide 2. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during this presentation, and you should

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot